A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention
Open Access
- 30 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (3), 614-625
- https://doi.org/10.1158/2159-8290.cd-20-0856
Abstract
A new mouse model of immune checkpoint inhibitor–induced myocarditis was developed, enabling the discovery that abatacept may be useful for ameliorating this condition; this finding was supported by results from a patient case series.Keywords
Other Versions
Funding Information
- Cancer Prevention and Research in Texas (R1203)
- NCI Cancer Center (P30CA16672)
- NIH Cancer Center (5P30 CA68485–19)
- the Vanderbilt Mouse Metabolic Phenotyping Center (2 U24 DK059637–16)
- NIH (R56 141466, R01 141466)
- NIH (R01CA227481)
- NIH (T32GM007347, F30CA236157)
This publication has 39 references indexed in Scilit:
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4Science, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2013
- Molecular mechanisms of T cell co-stimulation and co-inhibitionNature Reviews Immunology, 2013
- Pathogenesis and diagnosis of myocarditisHeart, 2012
- PD-1 deficiency results in the development of fatal myocarditis in MRL miceInternational Immunology, 2010
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005
- Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient miceNature Medicine, 2003
- Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient MiceScience, 2001
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995